MannKind Corporation (MNKD), Eli Lilly & Co. (LLY): The Easiest Prediction in Biotech This Summer

MannKind Corporation (NASDAQ:MNKD) is scheduled to release data for two phase 3 trials of its inhaled insulin, Afrezza, this month.

Nothing is for certain in biotech, but it looks to me like the extended phase 3 program has an extremely high likelihood of coming up positive. I’ll be shocked if both trials don’t meet their endpoints.

Why the clinical trials will be positive
Simply put, there isn’t that much difference between the product MannKind Corporation (NASDAQ:MNKD) studied in its previous successful phase 3 trials and the device used in its current trials, Affinity 1 and Affinity 2.

The new inhaler, dubbed Dream Boat, is smaller than MedTone, but there’s little reason to think the underlying insulin will do anything differently once it enters the body.


Source: MannKind.

In previous clinical trials, dubbed Study 102, Afrezza was able to lower A1C levels, a long-term measure of blood sugar levels, by about the same amount as injected insulin. Afrezza, which dropped A1C by 0.59 points, technically didn’t perform quite as well as injected insulin, which dropped A1C by 0.71 points, but the difference wasn’t great enough to say injected insulin was better.

MannKind Corporation (NASDAQ:MNKD)MannKind Corporation (NASDAQ:MNKD) thinks part of the reason why its A1C levels don’t look quite as good stems from the way the two products change blood sugar levels. Rapid-acting injected insulins, such as Novo Nordisk A/S (ADR) (NYSE:NVO)‘s NovoLog and Eli Lilly & Co. (NYSE:LLY)‘s Humalog, tend to produce lower fasting blood sugar levels compared to Afrezza. Hypoglycemia — low blood sugar levels — is extremely dangerous, so the long-acting insulin that diabetics also use is adjusted so the patient’s blood sugar level is high enough that the lows between meals don’t become too low.

Since the fasting lows aren’t nearly as low for patients taking Afrezza, patients can start with lower blood sugar levels. To produce parity, patients in the Affinity 1 trial are required to reduce their blood sugar level to a certain level before Afrezza or the rapid-acting insulin is tested.

If Afrezza can lower A1C levels more than injected insulins and/or produce fewer hypoglycemia events, it will make it much easier for MannKind Corporation (NASDAQ:MNKD) to take market share from NovoLog and Humalog.

The second trial, Affinity 2, compares Afrezza to placebo in type 2 diabetics who haven’t gone on insulin yet. We have less data on MannKind in this patient population, but the drug is being compared to placebo, so it shouldn’t be that hard to show insulin is capable of lowering blood glucose levels (that’s what it does naturally in those of us who don’t have diabetes).

All priced in
Despite the high likelihood of success, it’s hard to recommend buying MannKind Corporation (NASDAQ:MNKD) after the monster run it’s had this year.

MNKD Chart
MNKD data by YCharts.

Getting positive clinical trial data is only the first step. For MannKind Corporation (NASDAQ:MNKD) to justify its $2 billion market cap, the biotech needs to get the drug approved, find a partner, and build a market for Afrezza. Those risks are covered further in a companion article this weekend.

The article The Easiest Prediction in Biotech This Summer originally appeared on Fool.com and is written by Brian Orelli.

Fool contributor Brian Orelli has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

blog comments powered by Disqus
Insider Monkey Headlines
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months. Our beta is only 1.2 (don't click this link if beating the market isn't important to you).

Lists

Rito Pls Buff: The 10 Least Played Champions in LoL Season 4

10 Covers of Popular Songs that are Better than the Originals

Must See TV: The 9 Most Anticipated Shows of 2015

The 15 Biggest Box Office Bombs of All Time

10 Things The World Can’t Stand About Americans

Picture Perfect: The 6 Smartphones with the Best Cameras

The 10 Best Countries To Work In the World

A Profitable Day At The Track: 5 Tips For Betting On Horses

Tearing You Apart: 6 Bad Habits That Ruin Relationships

Learning on the Job: The 6 Biggest Mistakes Parents Make

Shopaholics Rejoice: The 12 Biggest Malls in the World

Fright Night: 10 Horror Movies Based on True Stories

Mach Mania: The 10 Fastest Jets in the World

Military Heavyweights: The 10 Countries with the Most Tanks

All In: The 7 Richest Poker Players in the World

Abracadabra: The 10 Best Magicians in the World

The 10 Richest Asian Countries in the World in 2014

Eyes in the Sky: 10 Things You Need to Know About Drones

Rising Stars: The 6 Best Silicon Valley Startups

Military Muscle: The 5 Most Advanced Armies in South America

All that Glitters: The 7 Most Luxurious Jewelry Brands in the World

5 Things You Didn’t Know About ISIS but Should

Empowering Your Money: The 5 Best Energy Stocks to Invest In

The 11 Best Android Apps You Can’t Get on iOS

The 10 Most Important International Conflicts in 2014

Mood Enhancers: The 20 Most Uplifting Songs of all Time

Lover Beware: The 8 Countries that Cheat the Most

Breath of Fresh Air: The 25 Countries with the Best Air Quality on the Planet

Singles Beware: The 8 Worst Mistakes Made on First Dates

Healthy and Happy: The 10 Countries with Lowest Healthcare Costs

The 6 Best Company Team Building Activities to Build Workplace Camaraderie

Ships Ahoy: The 10 Busiest Shipping Ports in the World

10 Productivity Tips to Save You Time and Help You Do More With Less

Grab a Bite: The Most Popular Fast Food Restaurants in America

Friday Night Thirst: The 10 Most Popular Cocktails in the World

The 6 Greatest Unsolved Mysteries We May Never Figure Out

7 Useless Products You Never Should’ve Bought

The 5 Reasons Why You’re Single and Miserable

The 7 Most Addictive Foods in the World We Can’t Stop Eating (Even Though We Should)

5 Amazing Places You Can Swim with Dolphins

The Top 7 Most Livable Countries In The World

The 10 Most Expensive Baseball Cards Ever Pulled From A Pack

The 5 Easiest Second Languages to Learn for English Speakers

Silver Spoon: The 6 Richest Families in the World

The 20 Countries with the Largest Prison Populations in the World

The Top 10 Richest Actors in the World

The 10 Best Airline Stocks to Invest In Before They Fly Too High

Burger Kings: The 10 Most Expensive Burgers in the World

The 10 Most Ethnically Diverse Countries in the World

The 10 Most Exclusive Credit Cards in the World

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!